The company’s broader OX2R portfolio includes clinical and preclinical assets with potential applications across neurological, neurodegenerative, and neuropsychiatric conditions
The US FDA has approved PONLIMSI (denosumab-adet) as a biosimilar to Prolia
The CDMO Leadership Awards spotlight top-performing development and manufacturing service providers
The investigational new drug application with FDA was actually for NEOK002, an EGFR/MUC1-targeting antibody-drug conjugate aimed at solid tumors
Kedar Upadhye has also been appointed as Chief Financial Officer of Biocon Limited
STADA will market and distribute two EMA approved biosimilars developed by CuraTeQ in select European Union territories
The move comes as drug developers face mounting pressure from faster timelines and increasingly complex manufacturing processes
Capital infusion to accelerate Earendil’s R&D platform
The Macau authorization followed a regulatory review that considered prior decisions by both the US FDA) and the European Medicines Agency
Subscribe To Our Newsletter & Stay Updated
